Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181292 | 0.90 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL507364 | 0.90 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL506784 | 0.90 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL29656200 | 0.89 | CYP2D6 (0.51) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL31662243 | 0.88 | CYP2D6 (0.48) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10376015 | 0.88 | CYP2D6 (0.67) | CYP2D6CYP1A2CYP3A4CYP2C19GAA | |
| SCHEMBL657896 | 0.88 | CYP2D6 (0.67) | CYP2D6CYP1A2CYP3A4CYP2C19GAA | |
| Fluoride SCHEMBL27871310 | 0.86 | CYP2D6 (0.61) | CYP2D6CYP1A2CYP3A4CYP2C19PKM | |
| SCHEMBL777214 | 0.84 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP3A4CYP2C19PKM | |
| SCHEMBL6198035 | 0.84 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP3A4CYP2C19PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| US-12384764-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4524139-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-03-19 | — | — | EP | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0962457-A1 | Piperidones as tachykinin antagonists | Pfizer Limited (GB) | 1999-12-08 | — | — | EP | disclosed |
| US-4702763-A | Herbicidal 1-aryl-delta2-1,2,4-triazolin-5-ones | FMC CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0157876-A1 | HERBICIDAL 1-ARYL-$g(D)?2 -1,2,4-TRIAZOLIN-5-ONES | FMC Corporation (US) | 1985-10-16 | — | — | EP | disclosed |
| WO-1985001637-A1 | HERBICIDAL 1-ARYL-DELTA2-1,2,4-TRIAZOLIN-5-ONES | FMC CORPORATION (US) | 1985-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | CYP2D6 1693/4885CYP1A2 2011/4885CYP3A4 831/4885 |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | CYP2D6 298/4885CYP1A2 296/4885CYP3A4 499/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | CYP2D6 2505/4885CYP1A2 1183/4885CYP3A4 1820/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | CYP2D6 51/4885CYP1A2 124/4885CYP3A4 73/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | CYP2D6 12/4885CYP1A2 15/4885CYP3A4 31/4885 |
| US-12384764-B2 | Pharmaceutical compounds | CNR1, HRH4, GABRA1 | CYP2D6 320/4885CYP1A2 602/4885CYP3A4 266/4885 |
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CYP2D6 1098/4885CYP1A2 460/4885CYP3A4 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.